Full-Time
Senior Frontend Engineer
Weave
51-200 employees
Generative AI platform for life-science collaboration
Compensation Overview
$175k - $225k/yr
San Francisco, CA, USA
Hybrid
Three days on-site per week required.
 Software Engineering (1) |
|---|
Get referred to Weave
See people who can refer or advise you
- 5+ years of production experience building modern web applications with React, TypeScript, and the broader frontend ecosystem (state management, bundlers, testing frameworks, design systems).
- AI-augmented engineering expertise. You're a skilled engineer first and you use AI-powered tools (e.g., Cursor, Claude) to meaningfully accelerate your workflow. You know how to leverage AI for code generation, exploration, debugging, and documentation while applying the deep technical judgment needed to evaluate, refine, and take full ownership of everything you ship. We're looking for engineers who treat AI as a force multiplier for their craft, not a substitute for it.
- Startup experience. You've worked at an early-stage, product-focused company (ideally <50 people) and know how to operate with autonomy, ambiguity, and limited resources.
- Strong product instincts. You think beyond the component; you consider the user journey, edge cases, accessibility, and how your work connects to business outcomes.
- Bias toward action with high standards. You move quickly without cutting corners. You know when to optimize and when to ship, and you're comfortable making that call.
- Pragmatic, clear thinking. You break down complex problems efficiently, make decisions with conviction, and communicate your reasoning to teammates.
- Collaborative mindset. You give and receive feedback generously, elevate the people around you, and care about the team's success as much as your own.
- Customer-centric problem solving. Deeply understand how customers use our product, then translate that understanding into intuitive, elegant frontend experiences.
- Collaborative product development. Partner closely with Product and Design to shape what gets built. You'll have a seat at the table from ideation through delivery.
- Real-time, collaborative editing. Architect and build a rich document editor with multiplayer collaboration features (think CRDTs, presence indicators, conflict resolution) that feels seamless at scale.
- High-quality frontend code. Write performant, well-tested TypeScript and React that your teammates (and your future self) will thank you for. We value readability, maintainability, and thoughtful abstractions.
- Technical direction. Drive software design decisions on your projects, managing conceptual and technical complexity so the codebase stays healthy as the product grows.
- Continuous delivery of value. Balance speed with quality. Ship iteratively, measure impact, and refine based on real-world usage.
- Experience building rich text editors or real-time collaborative features (e.g., Slate, ProseMirror, Yjs, Liveblocks).
- Familiarity with a regulated domain or a product where data privacy and security are first-class concerns.
- Contributions to open-source projects or a track record of sharing knowledge with the broader engineering community.
Weave.bio provides a platform for life sciences collaboration by integrating a generative AI system with a knowledge graph to connect researchers, data, and projects. The platform generates insights and maps connections across datasets, research teams, and workflows, while an incentive system rewards contributors proportionally to the value they add. Unlike tools that focus on a single function, Weave.bio combines collaboration features with a data-linking graph and an explicit rewards model to reduce silos and encourage sharing. The goal is to accelerate biomedical research and development, helping pharma, biotech, and academic researchers move from discovery toward real-world impact faster.
Company Size
51-200
Company Stage
Series A
Total Funding
$31.6M
Headquarters
New Haven, Connecticut
Founded
2023
Get referred to Weave
See people who can refer or advise you
Simplify's Take
What believers are saying
- Parexel partnership can accelerate enterprise distribution through CRO channels.[7]
- Expansion into clinical-stage submissions increases account expansion as programs advance.[7][8]
- Reported timeline reductions above 50% strengthen ROI for budget-constrained pharma teams.[7][11]
What critics are saying
- Veeva and IQVIA can bundle similar automation into entrenched workflows.
- FDA and EMA validation requirements slow adoption and add human-review overhead.[2][7]
- Submission errors in IND or clinical filings create rework, delays, and trust damage.[4][12]
What makes Weave unique
- AI-native regulatory platform spans authoring, review, publishing, and response management.[1][2]
- AutoIND generates eCTD-ready drafts from source data, guidelines, and public information.[4][11]
- Weave combines AI with human review for compliant, submission-ready dossiers.[5][7]
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -10%1 year growth
↓ -11%2 year growth
↓ -13%Weave Bio, an AI-driven regulatory automation company, has established its inaugural Strategic Advisory Board to guide the development of its platform and advance AI adoption in life sciences regulation. The board comprises senior executives from pharmaceutical companies and academia, including leaders from Takeda, Boehringer Ingelheim, Gilead, Stanford University and Serrado Capital. The SAB formation follows significant momentum for the San Francisco-based startup, which raised $20 million in Series A funding in October 2025 and announced a strategic partnership with Parexel. Weave Bio's platform streamlines regulatory content preparation for pharmaceutical companies, reducing regulatory timelines by over 50 percent whilst maintaining FDA and EMA compliance standards. Founded in 2022, Weave Bio has raised backing from investors including USVP, Innovation Endeavors and Magnetic Ventures.
Weave Bio raises $20M Series A to expand its AI-native platform that accelerates regulatory workflows for drug development.
Weave Bio raises $20M in Series A funding. Weave Bio, a San Francisco, CA-based provider of AI-native regulatory automation management solutions, raised $20m in Series A funding. The round, which brought total capital raised to $36m, was led by USVP, with participation by Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. The company intends to use the funds to accelerate product development and expand its commercial team. In details, Weave Bio will: * complete its coverage of the entire regulatory lifecycle of therapeutics, inclusive of market applications (NDA/BLA), responses to health authority questions (HAQ/RTQ), and post-market updates and submissions; * Expand into global markets beyond the U.S. FDA, including Europe, Japan, and Latin America; and * Build advanced AI capabilities that will provide insights into therapeutic portfolios and empower strategic decision-making across the drug development process. Led by Brandon Rice, CEO and co-founder, Weave Bio provides an AI-native, cloud-based, software platform that streamlines regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants. Weave infuses AI into every step of the workflow, from data extraction to authoring to review and data verification, to yield compliant, submission-ready regulatory dossiers with unprecedented speed.
Weave Bio has secured $20 million in Series A funding, led by USVP with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. This brings the company's total capital raised to $36 million. The funding will be used to enhance Weave's AI-native regulatory platform, expand global market reach, and build advanced AI capabilities. The platform aims to streamline regulatory workflows for pharmaceutical companies, biotech firms, and regulatory consultants.
Parexel announces AI partnership with Weave Bio to accelerate regulatory submission processes.